- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Featured Content
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Training for Operational Excellence
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Billions of Reasons to be Buoyant
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
Unpacking Amgen v. Sanofi
Aug 31st 2023
Exploring the state of pharma patents following the Supreme Court’s Amgen v. Sanofi decision.
Latest Videos
Latest News
GSK Seeks to Expand its Respiratory Biologics Portfolio with Aiolos Acquisition
February 21st 2024
GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.
BioVaxys Acquires Full Portfolio of Former IMV
February 15th 2024
BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.
Novartis to Acquire MorphoSys for Roughly $2.9 Billion
February 8th 2024
Through a €2.7 billion (US$2.9 billion) acquisition of MorphoSys, Novartis will get pelabresib, a late-stage drug candidate in development for cancer treatment.
Novo Holdings to Acquire Catalent in Deal Valued at $16.5 billion
February 5th 2024
Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.
Regeneron Forms R&D Cell Therapy Unit from 2seventy bio Platform Acquisition
February 1st 2024
With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.
IMU Biosciences Raises Millions in Series A Funding Round
January 30th 2024
IMU Biosciences has secured £11.5 million in its Series A financing round.
KBI Biopharma and Argonaut Manufacturing Services Team Up on Drug Substance and Drug Product Manufacturing Solutions
January 24th 2024
Under a new alliance, KBI Biopharma and Argonaut Manufacturing Services will combine their strengths to offer end-to-end biopharma development and CGMP manufacturing solutions.
Bora Pharmaceuticals Fuels Global Expansion with Acquisition in US
January 17th 2024
The acquisition marks a pivotal expansion for the company into the US market.
Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million
January 16th 2024
Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.
AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development
January 16th 2024
CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.